Streetbeat News

OKUR

OnKure Therapeutics, Inc.

Industry

Biotechnology

OnKure, Inc. engages in the discovery and development of oncology-precision medicines for the treatment of cancer. The company focuses on developing selective inhibitors of histone deacetylases. Its portfolio includes OKI-179, an inhibitor for the treatment of both hematological and solid tumors. The company was incorporated in 2011 and is based in Boulder, Colorado.

Open

3.18

Mkt cap

40M

Volume

68K

High

3.20

P/E Ratio

-0.19

52-wk high

20.00

Low

2.94

Div yield

N/A

52-wk low

2.57

OnKure Therapeutics has released its financial results for Q4 and the full year 2024. The company provided updates on its PIKture-01 trial, with additional pharmacokinetic data and mature single agent and initial combination data expected in H2 2025. Preliminary data reported in December 2024 was encouraging.

Portfolio Pulse from

March 10, 2025 | 8:15 pm

OnKure Therapeutics, Inc. (Nasdaq: OKUR) will present at upcoming Leerink and Stifel Investor Conferences. The company is a clinical-stage biopharmaceutical firm focused on developing novel precision medicines in oncology.

Portfolio Pulse from

March 04, 2025 | 1:15 pm

OnKure has rescheduled its investor call to discuss preliminary data from the PIKture-01 trial. The call is now set for December 10th at 7 a.m. CT.

Portfolio Pulse from

November 25, 2024 | 10:45 pm

HC Wainwright & Co. has initiated coverage on OnKure Therapeutics with a Buy rating and set a price target of $40.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2024 | 1:42 pm

Okur Cormorant Asset Management has reported a 14.98% passive stake in Onkure Therapeutics, according to an SEC filing.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2024 | 8:38 pm

OnKure Therapeutics Inc (NASDAQ:OKUR) has completed a merger with Reneo Pharmaceuticals and initiated trading. Oppenheimer has given OnKure an Outperform rating with a $35 price target, highlighting its innovative breast cancer treatment, OKI-219. The company has secured $65 million in private placement, ensuring a cash runway through Q4-2026. OKI-219 is noted for its selectivity in targeting PI3Kα mutations, offering a promising alternative to Novartis AG's (NYSE:NVS) alpelisib, which faces toxicity concerns.

Portfolio Pulse from Vandana Singh

October 10, 2024 | 6:43 pm

Top Wall Street analysts initiated coverage on several companies, including Align Technology, SiteOne Landscape Supply, OnKure Therapeutics, IperionX Limited, and Builders FirstSource. Notably, Builders FirstSource received a Buy rating from Goldman Sachs with a price target of $225.

Portfolio Pulse from Avi Kapoor

October 10, 2024 | 1:00 pm

Oppenheimer has initiated coverage on OnKure Therapeutics with an Outperform rating and set a price target of $35.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2024 | 12:07 pm

The trading halt status was updated at 8:55:00 AM ET, indicating a quotation resumption. This update is crucial for investors tracking the affected securities.

Portfolio Pulse from Benzinga Newsdesk

October 07, 2024 | 12:55 pm

Trading for a company has been halted at 7:20:34 a.m. ET due to pending news. This indicates that significant information is expected to be released, which could impact the stock price.

Portfolio Pulse from Benzinga Newsdesk

October 07, 2024 | 11:20 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.